Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Sells $24,657.50 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson sold 1,750 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $24,657.50. Following the completion of the sale, the chief accounting officer now directly owns 34,991 shares in the company, valued at approximately $493,023.19. This represents a 4.76 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Travis Alvin Thompson also recently made the following trade(s):

• On Monday, January 6th, Travis Alvin Thompson sold 2,686 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $15.00, for a total value of $40,290.00.
• On Monday, November 11th, Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $25.11, for a total value of $157,088.16.

Bicycle Therapeutics Trading Up 1.7 %

Shares of NASDAQ BCYC opened at $15.14 on Wednesday. The firm has a market capitalization of $1.05 billion, a P/E ratio of -4.60 and a beta of 0.92. The firm’s 50-day moving average price is $19.09 and its 200-day moving average price is $21.82. Bicycle Therapeutics plc has a 1-year low of $12.17 and a 1-year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $2.68 million for the quarter, compared to the consensus estimate of $6.82 million. During the same period in the prior year, the business earned ($1.26) EPS. The firm’s revenue for the quarter was down 50.0% on a year-over-year basis. Equities research analysts forecast that Bicycle Therapeutics plc will post -3.05 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $38.00 target price on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. HC Wainwright decreased their price objective on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a research report on Monday, December 16th. Royal Bank of Canada restated an “outperform” rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a report on Friday, November 1st. B. Riley decreased their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Finally, JMP Securities dropped their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research note on Wednesday, December 18th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Bicycle Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.

Hedge Funds Weigh In On Bicycle Therapeutics

Large investors have recently modified their holdings of the company. FMR LLC acquired a new position in Bicycle Therapeutics during the third quarter worth $3,406,000. TD Asset Management Inc increased its position in shares of Bicycle Therapeutics by 76.7% during the second quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock worth $1,967,000 after acquiring an additional 42,200 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Bicycle Therapeutics by 33.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock worth $2,935,000 after acquiring an additional 32,313 shares during the last quarter. Principal Financial Group Inc. bought a new position in Bicycle Therapeutics in the 3rd quarter valued at about $10,028,000. Finally, State Street Corp boosted its stake in Bicycle Therapeutics by 233.5% during the 3rd quarter. State Street Corp now owns 86,271 shares of the company’s stock valued at $1,952,000 after purchasing an additional 60,399 shares during the last quarter. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.